The DOI matches its Crossref record.
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy
Abstract
To the Editor,Therapeutic advancements for myeloid malignancies have increased treatment options for patients afflicted by these diseases, particularly those deemed unfit for intensive treatment op...
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The sequence of novel therapies may be highly relevant in this patient population.
“Notably, the sequence of novel therapies may be highly relevant in this patient population.”
From Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML (2025) · cites this paper as [48]
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 15
- 10.1200/EDBK_349605 · DOI
- 10.1186/s13045-023-01417-5 · DOI
- 10.1200/JCO.22.01794 · DOI · Paper page
- 10.1200/JCO.22.02604 · DOI
- 10.36401/JIPO-21-X2 · DOI
- Gilead. Gilead To discontinue phase 3 ENHANCE study of magrolimab plus azacitidine in higher-risk MDS [Internet]; 2023. Available from: https://www.gilead.com/news-and-press/press-room/press-releases/2023/7/gilead-to-discontinue-phase-3-enhance-study-of-magrolimab-plus-azacitidine-in-higher-risk-mds
- Gilead. Gilead statement on the discontinuation of magrolimab study in AML with TP53 mutations [Internet]; 2023. Available from: https://www.gilead.com/news-and-press/company-statements/gilead-statement-on-the-discontinuation-of-magrolimab-study-in-aml-with-tp53-mutations
- Zeidan AM, Platzbecker U, Bewersdorf JP, et al. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes. Blood. 2023;141:2047–2061.
- 10.1182/blood.2022016867 · DOI
- 10.1182/blood-2012-03-420489 · DOI
- 10.3324/haematol.2018.188094 · DOI
- 10.1200/JCO.22.00602 · DOI
- 10.1002/ajh.25000 · DOI
- 10.1182/bloodadvances.2018015529 · DOI
- 10.1002/cncr.30383 · DOI
Cited by
Sorted by citations
Sallman, D. A., Komrokji, R. S., Dezern, A. E., Sebert, M., Garcia‐Manero, G., Rahmé, R., Winer, E. S., Lehmann‐Che, J., Roboz, G. J., Madelaine, I., et al. (2025) · HemaSphere · doi:10.1002/hem3.70164 · Cited by 26
“48 Importantly, recent translational data have identified XPO1 as a critical target of resistance to eprenetapopt+ AZA, supporting a strong rationale for combination therapy with an XPO1 inhibitor such as selinexor or eltanexor.”
Metadata
- Authors
- Madero-Marroquin, R., Dworkin, E., Weiner, H., Saygin, C., Nawas, M. T., Drazer, M. W., DuVall, A. S., Kosuri, S., Thirman, M. J., Odenike, O., Stock, W., Larson, R. A., & Patel, A. A.
- Affiliations
- Department of Medicine, Section of Hematology/Oncology, University of Chicago
- University of Chicago (US)
- Corresponding author
- Patel, Anand A.
- ORCID
- Venue
- Leukemia & Lymphoma
- Publisher
- Informa UK Limited
- Published
- 2024-03-05
- Volume
- 65
- Issue
- 6
- Pages
- 864-867
- ISSN
- 1026-8022 (ISSN-L)
- 1042-8194
- 1029-2403
- OpenAlex
- W4392458700
- Cited by
- 2
- References
- 0
- Citations by year
- 2025: 2
- FWCI
- 0.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Leukemia & lymphoma/Leukemia and lymphoma (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
- Keywords
- venetoclax, combination therapy, treatment outcomes, myeloid neoplasms
- MeSH terms
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Myeloproliferative Disorders, Neoplasm Recurrence, Local, Sulfonamides, Treatment Outcome, Drug Resistance, Neoplasm, Bridged Bicyclo Compounds, Heterocyclic, CD47 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
